Foremost international breast cancer symposium highlights breakthroughs in research and treatment
The 33rd CTRC-AACR San Antonio Breast Cancer Symposium will feature the latest findings in prevention, epidemiological, laboratory, translational and clinical breast cancer research. This year's symposium will highlight new therapies in the pipeline, new approaches with existing agents and emerging biology that will affect the quest for personalized medicine.
To help you plan your coverage of the symposium, the program schedule is available at www.sabcs.org. An electronic press kit containing the press releases and highlighted abstracts will be available to subscribing reporters one week prior to the symposium via EurekAlert! and Newswise, and by request through the AACR Communications Department.
This year's CTRC-AACR San Antonio Breast Cancer Symposium will highlight:
- results of the AZURE trial, which will define the role of zolendronic acid;
- new data on the effect of obesity on risk and patient management;
- how clinicians might move beyond Herceptin in managing HER2 positive breast cancer;
- the role of circulating tumor cells in patient management and risk; and
- mammography compliance data in the general population.
The CTRC-AACR San Antonio Breast Cancer Symposium attracts world leaders in cancer research and treatment, including clinical oncologists, basic scientists, translational researchers and epidemiologists, working to improve prevention, diagnosis and patient care with the ultimate goal of eradicating breast cancer.
Dec. 8-12, 2010
Henry B. Gonzales Convention Center
San Antonio, Texas